95 related articles for article (PubMed ID: 8683244)
1. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group.
Kaye SB; Paul J; Cassidy J; Lewis CR; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM; Davis JA; Reed NS; Crawford SM; MacLean A; Parkin D; Sarkar TK; Kennedy J; Symonds RP
J Clin Oncol; 1996 Jul; 14(7):2113-9. PubMed ID: 8683244
[TBL] [Abstract][Full Text] [Related]
2. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
4. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
5. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
7. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.
Kaye SB; Lewis CR; Paul J; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM
Lancet; 1992 Aug; 340(8815):329-33. PubMed ID: 1353804
[TBL] [Abstract][Full Text] [Related]
8. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
9. Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Shapiro JD; Rothenberg ML; Sarosy GA; Steinberg SM; Adamo DO; Reed E; Ozols RF; Kohn EC
Cancer; 1998 Nov; 83(9):1980-8. PubMed ID: 9806657
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group.
Vasey PA; Paul J; Birt A; Junor EJ; Reed NS; Symonds RP; Atkinson R; Graham J; Crawford SM; Coleman R; Thomas H; Davis J; Eggleton SP; Kaye SB
J Clin Oncol; 1999 Jul; 17(7):2069-80. PubMed ID: 10561260
[TBL] [Abstract][Full Text] [Related]
11. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
12. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Conte PF; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
J Clin Oncol; 1996 Feb; 14(2):351-6. PubMed ID: 8636743
[TBL] [Abstract][Full Text] [Related]
13. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
14. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
[TBL] [Abstract][Full Text] [Related]
16. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
[TBL] [Abstract][Full Text] [Related]
17. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
Bolis G; Favalli G; Danese S; Zanaboni F; Mangili G; Scarabelli C; Tateo S; Valsecchi MG; Scarfone G; Richiardi G; Frigerio L; Melpignano M; Villa A; Parazzini F
J Clin Oncol; 1997 May; 15(5):1938-44. PubMed ID: 9164205
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
20. Short-duration (three cycles) cisplatin combination chemotherapy with alkylating agent consolidation in advanced epithelial ovarian cancer.
Lawton FG; Hilton C; Mould JJ; Chan KK; Blackledge G
Gynecol Oncol; 1991 Mar; 40(3):225-9. PubMed ID: 2013444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
